Acute myocarditis is an inflammatory disease of the heart muscle that may progress to dilated cardiomyopathy and chronic heart failure. A number of factors including the sex hormone testosterone, components of innate immunity, and profibrotic cytokines have been identified in animal models as important pathogenic mechanisms that increase inflammation and susceptibility to chronic dilated cardiomyopathy. The clinical presentation of acute myocarditis is non-specific and mimics more common causes of heart failure and arrhythmias. Suspected myocarditis is currently confirmed using advanced non-invasive imaging and histopathologic examination of heart tissue. However, the diverse presentations of myocarditis and the lack of widely available, safe, and accurate non-invasive diagnostic tests remain major obstacles to early diagnosis and population based research. Recent advances in the understanding of disease pathogenesis described in this review should lead to more accurate diagnostic algorithms and non-invasive tests.
- dilated cardiomyopathy
- cardiac magnetic resonance
- heart biopsy
- cardiac function
- endomyocardial fibrosis
- arrhythmic right ventricular dysplasia
- cardiomyopathy restrictive
- cardiomyopathy dilated
Statistics from Altmetric.com
- dilated cardiomyopathy
- cardiac magnetic resonance
- heart biopsy
- cardiac function
- endomyocardial fibrosis
- arrhythmic right ventricular dysplasia
- cardiomyopathy restrictive
- cardiomyopathy dilated
Acute myocarditis is an inflammatory disease of the heart muscle that may be confirmed using imaging and/or histopathologic criteria. Patients often report a viral prodrome of fever, rash, myalgias, arthralgias, fatigue and respiratory or gastrointestinal symptoms; these non-specific complaints typically precede the cardiovascular symptoms by a few days to weeks. The clinical presentation is variable and symptoms vary from mild dyspnoea or chest pain that resolve spontaneously to arrhythmias and cardiogenic shock.1 2 If the epicardium is involved, a syndrome of myopericarditis may develop with characteristic chest pain and sometimes pericardial effusion. Acute necrotising eosinophilic myocarditis and giant cell myocarditis are two rare idiopathic disorders that often present with fulminant or acute heart failure, and are frequently associated with ventricular arrhythmias or heart block. The clinical diversity of myocarditis and the lack of widely available, safe, and accurate non-invasive diagnostic tests have made its true incidence difficult to determine. In one series myocarditis was identified as a cause of unexplained dilated cardiomyopathy (DCM) in 9.6% of cases.3 In a registry of 1866 young athletes who died suddenly, 6% with cardiovascular disease (CVD) had myocarditis.4 Between 4% and 20% of sudden cardiovascular deaths among young adults, military service members, and athletes are due to myocarditis.5 Thus, myocarditis leads to a significant minority of DCM cases and contributes to the global burden of chronic heart failure.
Myocarditis can result from a wide spectrum of infectious pathogens including viruses, bacteria, spirochetes, fungi, and protozoans, as well as being induced by cardiotoxins and hypersensitivity reactions (table 1). Although most cases of suspected myocarditis are not linked to a specific aetiology, viral infection has been identified as the most common cause of myocarditis in Western Europe and North America. The most frequently identified virus in endomyocardial biopsies from myocarditis patients in the 1950s through the 1990s was coxsackievirus B, but adenovirus and parvovirus B19 have now become more prevalent.6 Although cardiovirulent coxsackievirus B strains reproducibly cause myocarditis and DCM in susceptible animal models, many wild type viruses from the same family evidently do not lead to cardiomyopathy in most human cases. The factors responsible for individual variations in susceptibility are not fully known but likely include genetic predisposition, sex hormones and/or sex chromosomes, and environmental factors like poor nutrition and vitamin deficiency.2
Pathogenesis of myocarditis
Most of the information about the pathogenesis of myocarditis and DCM comes from animal models rather than human studies. In animal models, the progression from acute myocarditis to chronic DCM can be simplified to a three-stage process: phase 1, cardiac injury and activation of the innate immune response; phase 2, acute myocarditis involving components of the innate and acquired immune response; and phase 3 recovery in resistant individuals versus progression to DCM in susceptible individuals (figure 1). A number of factors including sex hormones, particularly testosterone, components of innate immunity, and profibrotic cytokines have been identified in animal models as important pathogenic mechanisms that increase inflammation and susceptibility to chronic DCM (figure 1).
Phase 1: injury and activation of innate immunity
One of the hallmarks of myocarditis is injury to the myocardium. In animal models injury is induced by cardiotropic infections (ie, virus) that can damage cardiac tissue and/or by exposing animals to damaged self in the form of cardiac proteins or peptides (ie, cardiac myosin or troponins) in experimental autoimmune models. Damaged self proteins and infections (or adjuvants containing inactivated microbes) strongly induce the innate immune response, activating Toll-like receptors (TLRs) and the inflammasome, resulting in release of the proinflammatory cytokines tumour necrosis factor α (TNFα) and interleukin 1β (IL1β) (figure 1).7 8
A characteristic of the early innate immune response in mice that are susceptible to develop DCM (ie, BALB/c and A/J) is elevated levels of the proinflammatory cytokines TNFα and IL1β in the spleen and heart, and higher expression of TLR2 and TLR4 on innate immune cells like mast cells and macrophages.9–11 In humans and mice, TLR2 and TLR4 signalling has been demonstrated to be activated by damaged self proteins including cardiac myosin.12 13 TLR2 and TLR4 signalling increase TNF concentrations, and TLR2 acts synergistically with TLR4 to increase IL1β concentrations.14 Cardiac TLR4 mRNA expression has been found to be higher in patients with myocarditis than controls, and to correlate with viral RNA values in the heart.15 Myocarditis patients with active viral replication had higher concentrations of TLR4 that was associated with lower systolic function. Mice with defective TLR4 signalling have reduced acute experimental and viral myocarditis and reduced viral replication in the heart, indicating that TLR4 increases susceptibility to infection.16 17 For the most part, TLRs that protect the host from viral infections, such as TLR3, TLR7, TLR9 and their downstream adaptors MyD88 and TRIF, have been shown to reduce myocarditis and viral replication in animal models.13 18–20 Thus, data so far suggest that viral specific TLRs like TLR3 and TLR9 reduce acute myocarditis, while TLR2 and TLR4, which increase viral replication and the immune response to infection and damaged self, increase disease. Susceptibility in model systems to an elevated innate immune response is dependent on at least two factors: (1) male sex (eg, testosterone); and (2) genetic background (ie, T helper (Th)2 responding BALB/c mice) (figure 1).9 10 21 22
Phase 2: acute myocardial inflammation
Similar to findings in clinical biopsies of myocarditis patients, the primary infiltrate found in mouse models of acute myocarditis consists of macrophages and neutrophils with lower levels of T cells, B cells, mast cells, and dendritic cells.10 23 24 IL13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Natural killer cells, CD8 T cells and γδT cells, needed for antiviral defence, are also important in the early cardiac cellular response in viral animal models.25–27 TLR4 and IL1β remain elevated on mast cells and macrophages in the heart of susceptible male BALB/c mice during acute myocarditis (figure 1).10 28 IL1β and IL17 are known to induce cardiac remodelling that leads to fibrosis, DCM, and heart failure following acute myocarditis in mice.11 29–32 Regulatory mechanisms like Tim-3+ CD4 T cells, alternatively activated macrophages (M2), and regulatory T cells (Treg) are elevated at the later stage of acute myocarditis, resulting in the disappearance of acute inflammation from the heart of susceptible and resistant mouse strains.10 27 33–35
Phase 3: progression to DCM
Several weeks later in susceptible strains of mice (ie, BALB/c males) a low level inflammation re-emerges that is associated with myocyte necrosis, fibrosis, and DCM.35 36 TNFα and IL1β are elevated in the heart during acute myocarditis in mice and humans and are known to induce myocyte hypertrophy, contractile dysfunction, and myocyte apoptosis, and contribute to extracellular matrix remodelling—a step critical in the progression from myocarditis to DCM.11 16 29 37 Although acute myocarditis is characterised by a predominantly Th1 and/or Th17 response,17 32 38–40 only mice that develop a Th2 response during acute myocarditis, like BALB/c and A/J mouse strains, go on to develop the chronic stage of myocarditis associated with low level inflammation, necrosis, fibrosis, and DCM (figure 1).20 30 35 41 Profibrotic cytokines like TNFα, IL1β, IL4, IL17, and transforming growth factor β1 (TGFβ1) are believed to initiate remodelling during acute myocarditis that results in the appearance of cardiac fibrosis/scar tissue several weeks or months later.11 20 30 32 However, controversy remains concerning whether the primary mechanisms that lead to chronic DCM involve viral persistence, autoimmune or autoinflammatory derived damage.8 36 42 Many researchers contend that DCM is due to persistent viral replication in the heart, and have shown that persistent virus can induce cardiac inflammation, fibrosis, and necrosis.8 Other studies have found that virus persists within the heart of susceptible and resistant strains of mice, yet only susceptible mice develop chronic myocarditis and DCM.43 Additionally, adjuvant induced models of autoimmune myocarditis do not require virus persistence to induce chronic disease.32 36 41 The ability of testosterone to amplify acute and chronic myocarditis without altering viral replication requires further investigation.10 22 A better understanding of the mechanisms involved in the progression of myocarditis to DCM in susceptible individuals will enable researchers and clinicians to develop more effective therapeutic strategies to prevent dilation and heart failure.
Diagnosis of myocarditis
The gold standard for the diagnosis of myocarditis is the endomyocardial biopsy (EMB). However, most clinical settings have limited ability to perform EMB and the additive value of EMB, over clinical evaluation and non-invasive imaging, to refine prognosis and guide treatment in most cases of acute myocarditis is not established. The 2007 American Heart Association/American College of Cardiology Foundation/European Society of Cardiology (AHA/ACCF/ESC) scientific statement on the role of EMB in CVD limited the class I indications to only two relatively uncommon clinical scenarios.44 EMB should be performed in that small subset of adults who present with a sudden onset of severe heart failure requiring inotropic or mechanical circulatory support within 2 weeks of a viral illness, because they frequently can be bridged to recovery if they have lymphocytic myocarditis and survive the initial illness. Also patients who present with fulminant or acute DCM with sustained or symptomatic ventricular tachycardia, high degree heart block, or who fail to respond to standard heart failure treatment should be biopsied for possible giant cell myocarditis. When performed by experienced clinicians, EMB has a complication rate of <1% for both left and right ventricular biopsy.45
According to the Dallas criteria acute myocarditis is defined as histologic evidence of lymphocytic infiltrates in association with myocyte necrosis, while borderline myocarditis is characterised by inflammatory infiltrates without evidence of myocyte necrosis.46 The diagnosis of myocarditis using the Dallas criteria is limited due to potential inter-observer variability in interpreting histology sections.47 Although four to six biopsy samples are routinely obtained (using a Stanford-Caves bioptome), a postmortem analysis of proven myocarditis cases found that more than 17 samples are needed to diagnose myocarditis accurately in >80% of cases.48 More recent diagnostic criteria that are more sensitive define inflammation by a focal or diffuse mononuclear infiltrate (ie, CD3 stained T lymphocytes and/or CD68 stained macrophages) at >14 cells/mm.2 49 Immunohistological signs of inflammation also correlate with risk of death or transplantation over the following 10 years in patients with suspected myocarditis.50
Recent studies to refine diagnosis, predict prognosis, and guide therapy have used EMB as a research tool. For example, Heidecker et al recently used mRNA transcriptome profiles to distinguish myocarditis from non-inflammatory DCM.51 Smith et al used cells from EMB specimens to create ‘cardiosphere derived cells’ that promote cardiac regeneration.52 This technology is currently being used in the CADUCEUS trial for treatment of recent myocardial infarction.
Serum biomarkers provide valuable information for diagnosis of CVDs including myocarditis. For a biomarker to be clinically useful it should fulfil several criteria: (1) biomarker levels should be able to be accurately assessed using widely available and cost efficient methods; (2) biomarkers should provide additional information from the tests already conducted such as MRI; and (3) biomarker information should aid in medical decision making.53 A growing list of enzymes, hormones, markers of cardiac stress (eg, troponins) or necrosis (eg, Fas and Fas ligand), and cytokines (eg, IL10) have been examined as possible biomarkers for disease.
Troponins I and T
The release of cardiac troponins (I and T) from cardiomyocytes signals cell damage or death. Unfortunately, most studies suggest that a single value of troponin used for the diagnosis of suspected myocarditis has a low sensitivity.53 Lauer et al reported that 28 of 80 patients (35%) with clinically suspected myocarditis had elevated cardiac troponin T values.54 If a cut-off of >0.1 ng/ml was used, the sensitivity for troponin T to detect myocarditis was 53% and the specificity 94%.54 Smith et al evaluated the sensitivity of troponin I to detect myocarditis in a subgroup of patients from the Multicenter Myocarditis Treatment Trial, and found that the sensitivity was 34% and the specificity 89%.55 However, a gradual rise in troponin concentrations over more than 24 h, with a peak a day or more after the initial rise, may help distinguish myocarditis from acute ischaemic injury.
BNP and NT-proBNP
B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) are important indicators of cardiovascular stress and have the advantage of being able to distinguish acute from chronic heart failure. In contrast to troponins that are released due to cell wall compromise, BNP is synthesised in healthy cardiac myocytes from its precursor NT-proBNP.56 The prohormone BNP is only released to the circulation when the ventricles become dilated, hypertrophic or during other conditions that induce wall distension and stretching, and by neurohormonal activation. BNP has been found to be elevated in the serum of patients with myocarditis and DCM.53 57 58 Overall, BNP and NT-proBNP are biomarkers with a high sensitivity and specificity in predicting heart failure in a number of cardiovascular conditions including myocarditis and DCM.
Markers of inflammation
Non-specific serum markers of inflammation, including erythrocyte sedimentation rate, C reactive protein, and leucocyte count, are often elevated in myocarditis patients but seldom used for diagnosis. Elevated serum values of Fas and Fas ligand on initial presentation are associated with increased mortality in patients with acute myocarditis.59 Fas ligand is a membrane protein that belongs to the TNF family that induces apoptotic cell death when it binds to Fas and is converted to soluble Fas by matrix metalloproteinases (eg, MMP7). Fas has been shown to be notably increased on cardiac myocytes during acute viral myocarditis in mice, and myocardial inflammation is significantly decreased in Fas deficient mice.60 Fas is believed to cause cell death and myocardial necrosis indirectly by activating CD8+ T and NK (natural killer) cell mediated killing.60
Increased serum concentrations of the cytokines TNFα, IL1β, and IL10 have also been found to predict an increased risk of death in myocarditis patients.61 62 Serum concentrations of IL10 and TNFα were significantly higher in myocarditis patients compared to those patients with acute myocardial infarction, with IL10 values in particular predicting poor survival.61 IL1β and TNFα are thought of as prototypical proinflammatory cytokines. These two cytokines work synergistically to depress myocardial contractility, and their levels in sera have been shown to relate directly to New York Heart Association (NYHA) heart failure class and to predict patient mortality.62 In a separate study, cardiac TNF mRNA expression was found to be elevated more often in myocarditis patients when viral genomes were also detected, and greater mRNA values of TNF and its receptor TNFRI correlated with impaired cardiac function.63
Patients with myocarditis often develop autoantibodies against cardiac myosin or the β-adrenergic receptor. Anti-myosin antibodies are associated with left ventricular systolic dysfunction and diastolic stiffness in patients with chronic myocarditis.64 Anti-β1 receptor antibodies have been associated with greater risk of death or heart transplantation.65 Approximately 59% of myocarditis patients in one study were found to be positive for heart specific antibodies by immunofluorescence.66 In rodent models of myocarditis, anti-cardiac myosin antibodies have been shown to form immune complexes in cardiac tissue leading to apoptosis through β1-adrenoreceptor signalling.67
The diagnostic value of viral serology is limited by the fact that most viral infections believed to be involved in the pathogenesis of myocarditis are highly prevalent in the general population.68 The interpretation of viral antibody titres is complicated by confounders such as reactivation, reinfection, and/or cross-reactivity. Additionally, antibody levels vary over the time course of disease with the precise time of infection of individuals being largely unknown. IgM antibodies against parvovirus B19 are only detectable for a short period of around 2–10 weeks after acute infection, and so levels are likely to have resolved in many patients close to the time that they develop signs or symptoms of myocarditis.69
A positive viral serology does not indicate myocarditis, suggesting that assessing the presence of virus is not a particularly good diagnostic tool. Only five out of 124 (4%) patients with suspected myocarditis had serological evidence of infection with the same virus that was detected by reverse transcriptase-polymerase chain reaction (RT-PCR) in EMBs.70 The sensitivity for serological and EMB detection was 9% and the specificity was 77%, indicating that virus serology is not helpful for the diagnosis of myocarditis.70 Considering that immunohistological signs of inflammation rather than detection of viral genome were related to poor outcome in a large study of patients with suspected myocarditis,50 EMBs appear to be a better diagnostic tool than serologic testing for virus.
Electrocardiography (ECG) has a low sensitivity for diagnosing myocarditis. Non-specific ECG changes in myocarditis patients include sinus tachycardia, ST and T wave abnormalities, and ST elevations mimicking an acute myocardial infarction and occasionally atrial or ventricular conduction delays, as well as supraventricular and ventricular arrhythmias.71 Widened QRS and the presence of a Q wave are associated with higher rates of cardiac death or heart transplantation.72 None of these ECG changes correlate with myocarditis and cannot replace the ability of EMB to detect inflammation in patients with myocarditis.73
There are no specific echocardiographic features of myocarditis and it is used mainly to exclude other causes of heart failure such as valvular, congenital, or pericardial CVD.2 Impaired right ventricular function is a strong predictor of death or the need for cardiac transplantation and has been reported in 23% of patients with biopsy proven myocarditis.74 Patients with fulminant myocarditis tend to present with normal cardiac chamber dimensions and thickened walls compared with patients with less acute myocarditis who have greater left ventricular dilation and normal wall thickness.75 Thus, echocardiography has value in classifying patients with acute myocarditis and may provide prognostic information.
Cardiac MRI (CMR) is useful to distinguish ischaemic from non-ischaemic cardiomyopathy in the setting of acute DCM.76 Criteria suggested by an expert panel recommended that both T1 and T2 weighted imaging be used to obtain optimal sensitivity and specificity when myocarditis is suspected (table 2).77 When two or more of these ‘Lake Louise’ criteria are positive, acute myocardial inflammation can be predicted with a diagnostic accuracy of 78%. CMR in acute myocarditis may demonstrate regional rather than global involvement that evolves into inferolateral myocardial delayed enhancement, with sparing of the subendocardium.78 79 T1 weighted sequences obtained about 10 min after gadolinium injection (delayed) are perhaps the most reproducible, but not the most specific, for acute myocarditis.79 The combined application of CMR and EMB may yield diagnostic synergy (95%) and overcome some limitations of CMR or EMB as individually applied techniques.80
In the setting of myocarditis mimicking a suspected acute myocardial infraction with normal coronary arteries, CMR may demonstrate extensive TI enhancement in delayed images after gadolinium injection.81 Over the course of several months, the enhancement may decrease in intensity and distribution, with normalisation of left ventricular function.
The use of gene expression array technologies and proteomics will be valuable for identifying integrated biomarkers as well as pathogenic mechanisms that can be explored to improve interventions and therapy.51 A better understanding of the role of sex hormones on disease pathogenesis is needed. There is also a need for integrated biomarkers that will identify myocarditis at an earlier stage and predict development of chronic DCM. To improve our understanding of the pathogenesis of disease more translational studies between the clinic and animal researchers is required.
In the past decade, the diagnosis and prognosis of acute myocarditis has improved by using a combination of imaging and newer immunohistological staining techniques. Researchers using animal models of myocarditis have gained a better understanding of the pathogenesis of disease, particularly the importance of the sex hormone testosterone and innate immune mechanisms in driving the disease. There continues to be a need for better tools to assess the early stage of myocarditis/DCM and biomarkers that will more accurately identify individuals susceptible to develop DCM and heart failure.
Funding Dr Fairweather is supported by funding from the National Institutes of Health (R01 HL087033). Dr Cooper is supported by funding from the National Institutes of Health (R01 HL56267, Co-PI).
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.